RxDoctor Payments Data

Daniel Jasper

Internal Medicine · Saint Louis, MONPI 1730292509

Payments from drug & device makers

$5,019in general payments, 2019–2025

Across 289 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$710
  • AstraZeneca$436
  • Pfizer$369
  • Novo Nordisk$276
  • Amgen$185
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,994100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,019 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$146,076
Medicare patients
237
Services billed
1,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$74,018
EliquisApixaban65$67,383
MounjaroTirzepatide49$66,573
XareltoRivaroxaban39$49,019
FarxigaDapagliflozin Propanediol40$46,794
JardianceEmpagliflozin41$30,299
MyrbetriqMirabegron19$8,458
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,120
Butorphanol Tartrate11$6,985
ArexvyRsvpref3 Antigen/As01e/Pf18$5,088
Metoprolol Succinate246$3,159
SynthroidLevothyroxine Sodium40$3,023
Rosuvastatin Calcium203$2,790
Gabapentin74$2,034
Levothyroxine Sodium194$1,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$276$74,01880 claims
PfizerEliquis, Paxlovid$369$68,813105 claims
Lilly USA, LLCMounjaro$710$66,57349 claims
Johnson & JohnsonXarelto$75$49,01939 claims
AstraZenecaFarxiga$436$46,79440 claims
Boehringer IngelheimJardiance$157$30,29941 claims
GSKTrelegy Ellipta, Arexvy$57$12,20829 claims
Astellas Pharma US IncMyrbetriq$38$8,45819 claims
AbbVieSynthroid$1,170$3,02340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →